Intensive Glucose Control Increases Mortality in T2DM (ACCORD)
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2012 Nov 1;86(9):online.
Clinical Question: Does intensive glucose control in patients with type 2 diabetes improve outcomes more than usual control?
Bottom Line: This study confirms the initial findings of the ACCORD study: In middle-aged or older patients with cardiovascular risk factors, the best target for glycated hemoglobin is between 7.0% and 7.9%. (Level of Evidence: 1b)
Reference: The ACCORD study group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364(9):818-828.
Study Design: Randomized controlled trial (double-blinded)
Funding Source: Government
Setting: Outpatient (any)
Synopsis: The ACCORD study randomized persons aged 40 to 79 years with type 2 diabetes mellitus and known cardiovascular disease or cardiovascular risk factors to either intensive glucose control (glycated hemoglobin target < 6.0%) or usual control (7.0% to 7.9%). The study was stopped after 3.7 years when a significant increase in all-cause mortality was detected in the intensive therapy group. At that time, the median glycated hemoglobin levels were 6.4% and 7.5% in the intensive and usual treatment groups, respectively. At that time, the target for patients in the intensive therapy group was relaxed to a target glycated hemoglobin between 7.0% and 7.9%; follow-up continued for an additional 17 months. This report describes the results at the end of the entire 5 year follow-up period. At that time, the median glycated hemoglobin levels were 7.2% and 7.6%. Essentially, there was little difference between the outcomes of the original study and those at 5 years. Although nonfatal myocardial infarctions were still less common after 5 years (hazard ratio [HR] = 0.82; 95% CI, 0.7 - 0.96), cardiovascular and all-cause deaths (HR = 1.19; 1.03 - 1.38) were more common.
POEMs are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com.
Want to use this article elsewhere? Get Permissions